Incyte's KRAS G12D inhibitor shows 89% response rate in early pancreatic cancer trial
In a Phase 1 study, Incyte tested its KRAS G12D inhibitor together with standard chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma carrying the G12D mutation.
The combination produced a confirmed objective response in 89% of the 54 participants, with pending data indicating an 81% response rate. Disease control was reported in all patients.
Analysts described the data as positioning Incyte as a strong competitor in the KRAS G12D space, drawing comparisons to similar agents from other companies. If the results are confirmed in later-stage trials, the drug could become a notable option for a disease that has had limited therapies.
This writeup was produced by pharmadog from original reporting by BioSpace.
Original headline: “EMSO 2026: Incyte a ‘firm contender’ in G12D pancreatic cancer race as early candidate shines”
read at BioSpace ↗
comments(0)
5-min edit window · permanent after that